Tuvonralimab (Not yet branded)

Immunotherapy

US Experimental EU Experimental ES Not available IV 6 Clinical Trials
Unknown checkpoint protein

Description

Tuvonralimab is an experimental immunotherapy agent that appears in clinical trials for colorectal cancer, particularly in patients with BRAF V600E mutations and microsatellite stable (MSS) tumors. Based on trial data, it is being combined with chemotherapy regimens like FOLFIRI, TAS-102, and bevacizumab in metastatic colorectal cancer settings. The drug is also being evaluated in combination with radiotherapy for locally advanced colon cancer patients with proficient mismatch repair (pMMR) and MSS status.

Mechanism of Action

Tuvonralimab likely functions as an immune checkpoint inhibitor, though its specific molecular target is not definitively established from available clinical data. The drug appears designed to enhance immune system recognition and destruction of cancer cells by blocking inhibitory pathways that tumors use to evade immune surveillance.

Molecular Targets

Side Effects

Immune-related pneumonitis Colitis Hepatitis Skin rash Fatigue Diarrhea Endocrine dysfunction Infusion reactions

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07150247 Phase 2
Recruiting
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
China
NCT06949111 Phase 2
Recruiting
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
China
NCT07446387 Phase 2
Not yet recruiting
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
China
NCT07502014 Phase 2
Not yet recruiting
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
NCT07383285 Phase 2
Not yet recruiting
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
NCT07116577 Phase 2
Not yet recruiting
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
China

Quick Info

Brand NameNot yet branded
CategoryImmunotherapy
US StatusExperimental
EU EMA StatusExperimental
ES Spain AccessNot available
AdministrationIV
Clinical Trials6
View Clinical Trials Back to Drug Glossary

Related Medications

Bevacizumab
Immunotherapy
512 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials
Tislelizumab
Immunotherapy
62 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.